Treatments Autologous Stem Cell Transplants

This video details autologous stem cell transplants and offers insightful animations of the procedure.

In an autologous stem cell transplant, you are your own donor. Your peripheral blood stem cells are taken from you, frozen until needed, then given back to you after you have received high doses of radiation therapy, chemotherapy, or both, to destroy cancer cells.

“An autologous stem cell transplant removes your bone marrow stem cells so that you can be given larger doses of chemotherapy and radiation. Following therapy, your unharmed stem cells are returned”

Cancer Treatment Centers of America

A ‘huge leap forward’ for stem cell research

From usatoday.com

Scientists at the Stanford University School of Medicine may have taken the controversy out of the entire field of stem cell research.

In a paper published online today in the journal Nature, they report that they were able to transform mouse skin cells directly into functioning nerve cells without needing to go through a stem cell stage first.

As they say in their paper, this “could have important implications for studies of neural development, neurological disease modeling and regenerative medicine.”

Click link above for complete article.

International Stem Cell Corporation Progresses towards Establishment of the Industry’s First Universal Stem Cell Bank, UniStemCell™

OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that it has signed up the first two in vitro fertilization (IVF) clinics and engaged an experienced pharmaceutical industry executive to lead the establishment of the company’s universal stem cell bank, UniStemCell™. International Stem Cell Corporation has made breakthrough stem cell discoveries that result in unique advantages over the only two other proven methods of making human pluripotent stem cells. In particular, for the first time in industry history, this will enable the establishment of a bank containing a manageable number of stem cell lines that will be immunological matches for large patient populations of different ethnic origin.

“By combining the proven oocyte retrieval experience and clinical excellence of California Center for Reproductive Medicine and Acacio Fertility Center with the pharmaceutical and operational experience of Dr. Craw, International Stem Cell Corporation is well positioned to generate the world’s first cGMP quality hpSC lines in 2010.”

The company uses unfertilized eggs (oocytes) to create human “parthenogenic” stem cells (hpSCs). Like embryonic stem cells (ESCs), hpSCs are pluripotent (i.e. have the capacity to become almost any cell type in the body), yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike induced pluripotent stem cells (iPSs), hpSCs do not involve extensive gene manipulation, which may have unknown biological impact. Unlike both ESCs and iPSs, hpSCs can be created in a homozygous form such that each line will be an immunological match for millions of patients.

International Stem Cell Corporation has partnered with two IVF clinics in Southern California, California Center for Reproductive Medicine under the leadership of Dr. Lori Arnold and Acacio Fertility Center under the leadership of Dr. Brian Acacio. Both clinics provide exceptional clinical care for egg donors and IVF patients, not only regionally but across the US and abroad. California Center for Reproductive Medicine and Acacio Fertility Center provide a US source of oocytes under full regulatory and medical oversight that allow for the creation of the first clinical grade hpSC lines anywhere in the world. Dr. Acacio says: “We look forward to participating in this important research with the ultimate goal of each egg donation not only helping a single couple but millions of people with degenerative diseases.” Dr. Arnold says: “While we provide world-class care for our IVF patients, we are excited to add our clinical expertise and join International Stem Cell Corporation in this medical frontier of regenerative medicine.”

Click here for complete article.

Neuralstem Announces First Patient Treated in ALS Stem Cell Trial

ROCKVILLE, Md., Jan. 21 /PRNewswire-FirstCall/ — Neuralstem, Inc. (NYSE Amex: CUR) announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA.  A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig’s disease).  ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.

“The treatment of the first patient with our spinal cord stem cells represents a significant milestone for the Company,” said Neuralstem President and CEO, Richard Garr.

Click here for complete article.

First Successful Use of Expanded Umbilical-Cord Blood Units to Treat Leukemia

ScienceDaily (Jan. 18, 2010) — Scientists at Fred Hutchinson Cancer Research Center have cleared a major technical hurdle to making umbilical-cord-blood transplants a more widely-used method for treating leukemia and other blood cancers.

Click link for more.

Primetime Special on Cord Blood Stem Cell Therapy

Two cerebral palsy patients and CBR clients who are experiencing positive results after undergoing reinfusion of their own cord blood stem cells were featured on the NBC San Francisco Bay Area show Health Matters: Stem Cell Therapy Today & Tomorrow.

Stem Cells: Developing New Cures

New York Stem Cell Foundation (NYSCF) has helped create a video on stem cell research currently playing in the Hall of Human Origins at the American Museum of Natural History in New York. It portrays the promise of stem cell therapies for human disease and demonstrates the potential of the research to create opportunities for studying disease fundamentals.

Stem Cells: Developing New Cures from NYSCF on Vimeo.

5th Annual Summit to Feature New Stem Cell Therapies

WAYNE, Pa., Jan. 8 /PRNewswire/ — Six new stem cell therapies, all forecast to reach physicians in 2010, will be featured at the 5th Annual Stem Cell Summit on February 16 in New York City. These new therapies include allograft products, innovative forms of autologous stem cell technologies, and at least one FDA-approved stem cell drug. New studies showing rehydration of the disc nucleus, regeneration of new heart muscle and others are also on the agenda.

The Stem Cell Summit is an annual gathering of stem cell and biomaterial company executives, scientists and investors to explore the therapeutic applications of stem cells, the successful path to stem cell product commercialization, and the latest investment opportunities within the space. The Summit features 35 corporate presentations, a scientific panel, separate tracks for stem cell tools & instruments, and a closing reception. It is an intensive one-day event held at Bridgewaters in New York City’s historic South Street Seaport.

The presenting stem cell companies include:

Aastrom Biosciences, Inc.        INCELL Corporation, LLC
AllCells, LLC                            International Stem Cell Corp.
AlloSource                               Lonza Group Ltd.
Aldagen, Inc.                           MaxCyte, Inc.
ArunA Biomedical, Inc.            Mesoblast Limited
Athersys, Inc.                           Novocell, Inc.
BioE Inc.                                   Osiris Therapeutics, Inc.
Cardiogenesis Corp.                 Pluristem Therapeutics Inc.
Cellerix, S.A.                             ProChon Biotech, Ltd.
Celtigen Therapeutics, LLC      Progenitor Cell Therapy, Inc.
Core Dynamics Ltd.                   SpineSmith Partners LP
Cytori Therapeutics, Inc.           Stematix, Inc.
Gamida Cell Ltd.                        Stemina Biomarker Discovery, Inc.
Garnet BioTherapeutics, Inc.    TiGenix NV
Genzyme Biosurgery                  Tissue Genesis, Inc.
Glycosan BioSystems, Inc.         TxCell SA
Harvest Technologies Corp.      Vet-Stem, Inc.
Histogen, Inc.

In addition to the company and scientific presentations, Robin R. Young, CFA, a leading medical technologies analyst, will deliver his updated 10-year market forecast for the industry. “In 2009, the number of new market entrants was notable, but there were some difficulties with regard to clinical trials. Nevertheless, sales of stem cell therapies continue to grow extremely rapidly in the United States. We now estimate that revenues from stem cell therapies will surpass $2.5 billion by 2015 and that the industry will support a $10 billion valuation,” said Young.

5th Annual Stem Cell Summit Facts at a Glance

When:  Tuesday, February 16, 2010

Where:  Bridgewaters
11 Fulton Street
New York City

Admission:  $1,200 advance registration by January 31, 2010
$1,500 (February 1 – 16, 2010)

Information: A detailed agenda and online registration are available at www.stemcellsummit.com.

Adult Stem Cells Success Stories – Amy Daniels

StemCellResearchFacts.com – Amy Daniels was terrified when she learned that she had Scleroderma- a disease that causes the tissue in the skin, blood vessels, and muscles to harden. It’s known as the disease that turns people into stone. Amy was fortunate to get into a medical study that used Adult Stem Cells from her own body to save her life. She is now completely cured from the disease.

Life Science Stocks: A Growing Market in 2010

By David Bogoslaw, Sci-tech-today.com

What if doctors had a detailed road map of the kinds of drugs and therapies that your own personal genetic makeup makes you most receptive to, instead of having to arrive at effective treatments through the costly — and sometimes painful — method of trial and error? That’s the promise of the nascent field of personalized medicine.

click link above for complete article.